Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Blue Trust Inc.

Blue Trust Inc. grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 896.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 568 shares of the biotechnology company’s stock after buying an additional 511 shares during the period. Blue Trust Inc.’s holdings in Sarepta Therapeutics were worth $71,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of SRPT. Wealth Enhancement Advisory Services LLC boosted its stake in Sarepta Therapeutics by 100.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,996 shares of the biotechnology company’s stock worth $647,000 after buying an additional 2,504 shares during the period. Commonwealth Equity Services LLC boosted its position in shares of Sarepta Therapeutics by 8.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 5,243 shares of the biotechnology company’s stock worth $679,000 after purchasing an additional 418 shares during the period. Van ECK Associates Corp increased its holdings in Sarepta Therapeutics by 5.3% in the 1st quarter. Van ECK Associates Corp now owns 86,329 shares of the biotechnology company’s stock valued at $11,176,000 after purchasing an additional 4,374 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Sarepta Therapeutics by 111.3% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 90,945 shares of the biotechnology company’s stock valued at $12,131,000 after purchasing an additional 47,895 shares during the period. Finally, Connecticut Wealth Management LLC acquired a new position in Sarepta Therapeutics during the first quarter worth $261,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Price Performance

SRPT stock opened at $127.78 on Thursday. The stock has a market cap of $12.08 billion, a price-to-earnings ratio of 1,161.64 and a beta of 0.82. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The business has a 50 day moving average price of $128.07 and a 200 day moving average price of $132.57.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same period last year, the firm posted ($0.27) EPS. The company’s revenue was up 38.9% on a year-over-year basis. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of the stock in a transaction on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the transaction, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $152.00 target price on shares of Sarepta Therapeutics in a research report on Friday, September 20th. Barclays reduced their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Needham & Company LLC reissued a “buy” rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 14th. Finally, Piper Sandler cut their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $182.95.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.